The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
暂无分享,去创建一个
Makoto Nishio | Peter McNamara | Ryohei Katayama | Naoya Fujita | Sidra Mahmood | Nanxin Li | Sungjoon Kim | Nanxin Li | Jennifer L. Harris | J. Engelman | P. McNamara | A. Shaw | Ryohei Katayama | N. Fujita | S. Kasibhatla | Xiuying Sun | M. Nishio | Christian C. Lee | J. Gainor | M. Awad | Jeffrey A Engelman | Jie Li | Alice T Shaw | Justin F Gainor | Elizabeth L Lockerman | N. Yanagitani | Luc Friboulet | Jennifer L Harris | Mark M Awad | Christian C Lee | Xiuying Sun | Su Hua | Sungjoon Kim | Pierre-Yves Michellys | Adam S Crystal | Noriko Yanagitani | AnneMarie C Pferdekamper | Shailaja Kasibhatla | Frank Sun | L. Friboulet | Sidra Mahmood | Jie Li | A. Crystal | P. Michellys | Elizabeth Lockerman | F. Sun | A. Pferdekamper | Su Hua | S. Hua
[1] T. Clackson,et al. Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen , 2011, Chemical biology & drug design.
[2] Wei Zheng,et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.
[3] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[4] Glen Spraggon,et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. , 2010, The Biochemical journal.
[5] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[6] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[7] A. Iafrate,et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.
[8] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[9] M. Marra,et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma , 2012, Disease Models & Mechanisms.
[10] Wei Zheng,et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.
[11] William Pao,et al. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance , 2012, Science Translational Medicine.
[12] Ryohei Katayama,et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.
[13] J. Christensen,et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.
[14] Sungjoon Kim,et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 , 2013, Journal of medicinal chemistry.
[15] Tatiana G. Kutateladze,et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[16] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[17] J. Engelman,et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. , 2013 .
[18] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.